)
Visual21 Nov 2025
Data center suppliers
Pila Pharma (PILA) investor relations material
Pila Pharma Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary27 Aug, 2025
Executive summary
Strategic focus shifted to obesity drug development alongside type 2 diabetes, driven by industry feedback and market opportunity, with strong engagement from pharmaceutical partners interested in differentiated TRPV1 antagonist approaches.
The company completed an oversubscribed rights issue, raising nearly SEK 30 million before costs, providing a solid financial base for upcoming studies.
Management and board members increased their holdings, with significant set-offs for executive remuneration, now holding about 15% of shares.
Positive industry response to the TRPV1 antagonist project, with plans to demonstrate Proof of Concept in preclinical and clinical obesity studies.
The company is preparing to announce a top-tier preclinical partner for upcoming studies.
Financial highlights
Operating income for H1 2025 was TSEK 851, up from TSEK 683 year-over-year.
EBIT for H1 2025 was TSEK -4,092, nearly unchanged from TSEK -4,082 in H1 2024.
Net result for H1 2025 was TSEK -4,102, compared to TSEK -4,086 in H1 2024.
Cash at period end was TSEK 1,082, down from TSEK 2,543 at June 2024, with significant improvement post-period due to the rights issue.
Burn rate remained consistent with the previous half-year period.
Outlook and guidance
Preclinical in vivo rat studies for obesity are set to begin in autumn, with results expected before the TO2 warrant exercise period in February 2026.
Pending positive preclinical results and continued funding, clinical trials in humans with obesity are planned.
Funds raised are sufficient to finance rat obesity studies and clinical trial application preparations for both diabetes and obesity.
No official runway guidance, but current funding is sufficient for planned preclinical activities.
Additional funding possible from warrant exercise, potentially up to SEK 90 million.
Outline obesity development path
What patient needs does your drug address?
How does funding impact study execution risk?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Pila Pharma earnings date
Q4 202526 Feb, 2026
Next Pila Pharma earnings date
Q4 202526 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
PILA PHARMA AB (publ) is a clinical stage pharmaceutical company developing XEN-D0501, a TRPV1 antagonist targeting the prevention and treatment of type 2 diabetes. The product candidate has completed two phase 2a clinical trials. Once it completes its ongoing phase 2b trial, PILA PHARMA AB (publ) is planning to initiate pivotal phase 3 study.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage